Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a flagellin, and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased T-cell and antibody mediated immune responses specific for the heterologous disease-associated antigen when administered to a subject, e.g. a human subject, and related methods and uses.

A minimal antigen delivery system consists essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class restricted peptide and surface modified with a cell targeting peptide which mediates binding and internalization of the liposomes into a target cell.

A minimal antigen delivery system consists essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class restricted peptide and surface modified with a cell targeting peptide which mediates binding and internalization of the liposomes into a target cell.

Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.

Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.

Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVAΔC7L and VACVΔC7L, respectively), alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVAΔC7L or VACVΔC7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).

Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVAΔC7L and VACVΔC7L, respectively), alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVAΔC7L or VACVΔC7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).

The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.

The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.

Pharmaceutical compositions and pharmaceutical combination preparations. The pharmaceutical compositions and the pharmaceutical combination preparations comprise at least one oxidative stressor selected from the group consisting of dithranol (anthralin, cignolin), or other anthrones or hydroxyanthracenes, at least one Toll-like receptor 7 (TLR7) ligand, and at least one peptide antigen. The pharmaceutical compositions or combination preparations may be used in the prevention or treatment of a persistent viral, bacterial or fungal infection or of cancer. The pharmaceutical compositions or combination preparations may find use for topical application on the skin of a human or animal body.